{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"25.0"},{"groupId":"OG003","value":"20.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Deaths due to any cause during treatment and 30 day follow-up","groups":[{"description":"Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive","id":"OG000","title":"Anaplastic Large Cell Lymphoma (ALCL)"},{"description":"Patients diagnosed with IMT with a confirmed translocation involving the ALK gene","id":"OG001","title":"Inflammatory Myofibroblastic Tumor (IMT)"},{"description":"Patients with GBM with a translocation involving the ALK gene","id":"OG002","title":"Glioblastoma (GBM)"},{"description":"Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).","id":"OG003","title":"Any Other ALK-positive Tumor"}],"paramType":"NUMBER","populationDescription":"There were no deaths in the ALCL and IMT arms","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 84 weeks","title":"Percent of Participant Deaths During Treatment and Follow-up","type":"SECONDARY","unitOfMeasure":"percent of participants"}